Recently, the State Drug Administration approved the marketing of amfricitamab injections declared by Sansheng Guojian Pharmaceutical Co., Ltd., which are suitable for acute attacks of gout arthritis in adults who are contraindicated, intolerant or lack curative effects of nonsteroidal anti-inflammatory drugs and/or colchicine, and are unsuitable for repeated use of steroids. The marketing of this variety provides new treatment options for relevant patients. Recently, the State Drug Administration passed a priority review and approval procedure to approve the marketing of the Class 1 innovative drug, rikonkopan fumarate capsules, declared by Chengdu Shengdi Pharmaceutical Co., Ltd., for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors. The launch of this drug provides patients with new treatment options.

Recently, the State Drug Administration approved the marketing of amfricitamab injections declared by Sansheng Guojian Pharmaceutical Co., Ltd., which are suitable for acute attacks of gout arthritis in adults who are contraindicated, intolerant or lack curative effects of nonsteroidal anti-inflammatory drugs and/or colchicine, and are unsuitable for repeated use of steroids. The marketing of this variety provides new treatment options for relevant patients. Recently, the State Drug Administration passed a priority review and approval procedure to approve the marketing of the Class 1 innovative drug, rikonkopan fumarate capsules, declared by Chengdu Shengdi Pharmaceutical Co., Ltd., for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors. The launch of this drug provides patients with new treatment options.